Successful AZD9291 Therapy Based on Circulating T790M

Slides:

Advertisements

Similar presentations

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Advertisements

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Lungs on Fire Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

MET Mutation Associated with Responsiveness to Crizotinib

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

MET-Mutated NSCLC with Major Response to Crizotinib

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion Eckart Laack, MD, Ronald.

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

The Moth-Eaten Lung Journal of Thoracic Oncology

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Aya Fukuizumi, MD Journal of Thoracic Oncology

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Solange.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification.

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Chien-Wei Chen, MD, Chin-Wei Kuo, MD Journal of Thoracic Oncology

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Nicholas W. Choong, MD, Robert S. Hellman, MD

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Metastatic Lung Cancer to the Pancreas

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Successful AZD9291 Therapy Based on Circulating T790M Oliver Gautschi, MD, Stefan Aebi, MD Journal of Thoracic Oncology Volume 10, Issue 12, Pages e122-e124 (December 2015) DOI: 10.1097/JTO.0000000000000676 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A–C, Pretreatment 18FDG-PET/CT showing the primary tumor in the right lung, disseminated nodal and skeletal metastases, with strong uptake in the fourth thoracic vertebrae (B), and in the left sacrum and ilium (C). 18FDG-PET/CT at 6 weeks (D–f) and 12 weeks (C–I) weeks after start of treatment with AZD9291, showing metabolic and morphological tumor response, and persistent pleural effusion (E). 18FDG-PET/CT, 18F-deoxyglucose positron emission tomography with computer tomography. Journal of Thoracic Oncology 2015 10, e122-e124DOI: (10.1097/JTO.0000000000000676) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Allele frequency of EGFR T790M in the plasma by NEOLiquid (NEO New Oncology AG, Cologne, Germany) before the start of AZD9291 treatment (A), and after 2 weeks (B), 4 weeks (C), 6 weeks (D), and 12 weeks (E). The vertical dashed black line depicts the positional nucleotide change of C>T in exon 790 of EGFR, resulting in the T790M mutation. Journal of Thoracic Oncology 2015 10, e122-e124DOI: (10.1097/JTO.0000000000000676) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions